PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 22, 2026Current Drug Research Reviews0 citations

Exploring the Role of Neuropeptide Y in Neurodegenerative Diseases: Drug Candidates Modulating Npy Activity

View Full Paper
NRNikita D. RahangdaleKTKalyani R ThombreKGKrishna R. Gupta

Key Points

  • The study explores the role of neuropeptide Y in various neurodegenerative diseases and its therapeutic potentials.
  • Investigated the effects of neuropeptide Y on neurodegenerative diseases.
  • Analyzed its interaction with G-protein-coupled receptors.
  • Evaluated the impact of NPY on excitotoxicity, oxidative stress, and inflammation.
  • NPY modulates key processes in Alzheimer's, Parkinson's, and Huntington's diseases.
  • It enhances synaptic plasticity and memory retention in Alzheimer's.
  • NPY protects dopaminergic neurons in Parkinson's, reducing motor impairments.

Abstract

The 36-amino-acid peptide neurotransmitter known as neuropeptide Y (NPY) is extensively dispersed throughout the central and peripheral nervous systems. It belongs to the pancreatic polypeptide family and is essential for controlling hunger, stress reactions, heart health, and neuroprotection. Through G-protein-coupled receptors (Y1, Y2, Y4, and Y5), which are implicated in synaptic plasticity, emotional stability, and energy balance, NPY produces its effects. In neurodegenerative diseases like Alzheimer's, Parkinson's, Huntington's, and Machado-Joseph's, NPY is a crucial modulator. By decreasing excitotoxicity, oxidative stress, and inflammation and improving synaptic plasticity and memory retention, NPY has neuroprotective effects in Alzheimer's disease. It lessens the loss of dopaminergic neurons in Parkinson's disease, which lessens motor impairments. NPY prevents striatal neurons from degenerating in Huntington's disease, and it controls oxidative stress and neuroinflammation to improve neuronal survival in Machado-Joseph disease. In mood disorders like anxiety and depression, where its dysregulation is associated with increased susceptibility to stress, NPY also plays a crucial role. One possible treatment strategy for these disorders is to target NPY receptors. NPY-based treatments for metabolic, cardiovascular, and neuropsychiatric conditions are investigated in pharmacological research. It has been discovered that substances like cocaine, amphetamines, nicotine, and opioids change the expression of NPY, affecting the brain's regulatory processes. MK-0557 and Velneperit are two examples of Y-receptor agonists and antagonists that have been studied in clinical trials for the treatment of obesity. NPY is a promising target for the treatment of metabolic, cardiovascular, neurodegenerative, and psychiatric disorders due to its multifunctional role. In order to enhance neuroprotection and improve treatment outcomes, future research should concentrate on creating NPY-based therapies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Rahangdale et al. (2026) studied this question.

synapsesocial.com/papers/69bf393dc7b3c90b18b4386ahttps://doi.org/10.2174/0125899775402435251203050736
Ask AI
Helpful
Bookmark
Share
View Full Paper